TABLE 5.
Antibiotic resistance phenotypes of 25 transconjugants using Gram-negative susceptibility panels (CMV4AGNF and ESB1F) on the Sensititre automated systema,b
| Antibiotic(s) | Phenotype for transconjugant |
||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| T156A | T247A | T277A | T224A | T413A | T308A | T257A | T455A | T199A | T295A | T304A | T306A | T476A | T409A | T478A | T496A | T082A | T270A | T145A | T159A | T101A | T267A | T286A | T221A | T209A | |
| Amoxicillin/clavulanic acid | S | S | S | S | S | S | S | S | I | I | I | I | I | I | I | I | I | R | S | R | R | R | R | R | R |
| Ampicillin | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R |
| Azithromycin | S | S | S | S | R | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S |
| Cefazolin | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R |
| Cefepime | S | S | S | S | S | S | S | S | R | S | R | S | S | R | R | R | R | R | S | R | R | R | R | R | R |
| Cefotaxime | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R |
| Cefoxitin | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S | I | S | S | S | S | S | S | S |
| Cefpodoxime | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R |
| Ceftazidime | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R |
| Ceftriaxone | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R |
| Cephalothin | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R |
| Chloramphenicol | S | S | S | S | S | S | S | S | S | S | R | R | S | R | R | R | R | R | S | R | R | R | R | R | R |
| Ciprofloxacin | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S |
| Gentamicin | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S |
| Imipenem | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S |
| Meropenem | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S |
| Nalidixic acid | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S |
| Piperacillin/tazobactam | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S | I | S | S | S | S | S | S | S |
| Streptomycinc | S | S | S | S | R | S | S | S | S | S | R | R | S | R | R | R | R | R | S | R | R | R | R | R | R |
| Sulfisoxazolec | S | S | S | S | NS | S | S | S | S | NS | NS | NS | S | NS | NS | NS | NS | NS | S | NS | NS | NS | NS | NS | NS |
| Tetracycline | S | S | S | S | R | S | S | S | S | R | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S |
| Trimethoprim/sulfamethoxazole | S | S | S | S | S | S | S | S | S | R | R | R | S | R | R | R | R | R | S | R | R | R | R | R | R |
The results were interpreted by the Sensititre automated system unless otherwise stated.
Streptomycin and sulfisoxazole results were interpreted according to the breakpoint guideline provided by U.S. Food and Drug Administration (FDA) (https://www.fda.gov/media/108180/download).
R, resistant (bolded for clarity); I, intermediate; S, susceptible; NS, not susceptible. NS only applies to sulfisoxazole where MICs were limited by the range of tested panels; however, the values were larger than the susceptible breakpoint in the guideline provided by U.S. Food and Drug Administration (FDA) (https://www.fda.gov/media/108180/download).